Handheld near-infrared imaging device enables quick detection of hematomas

When accidents that involve traumatic brain injuries occur, a speedy diagnosis followed by the proper treatment can mean the difference between life and death. A research team, led by Jason D. Riley in the Section on Analytical and Functional Biophotonics at the U.S. National Institutes of Health, has created a handheld device capable of quickly detecting brain injuries such as hematomas, which occur when blood vessels become damaged and blood seeps out into surrounding tissues where it can cause significant and dangerous swelling.

A paper describing the team's proof-of-concept prototype for the hematoma detection device appears in the Optical Society's (OSA (http://www.osa.org)) open-access journal Biomedical Optics Express (http://www.opticsinfobase.org/boe). The device is based on the concept of using instrumental motion as a signal in near-infrared imaging, according to the researchers, rather than treating it as noise. It relies on a simplified single-source configuration with a dual separation detector array and uses motion as a signal for detecting changes in blood volume in the tough, outermost membrane enveloping the brain and spinal cord (see video (http://www.osa.org/About_Osa/Newsroom/News_Releases/Releases/12.2011/Monthly-Tip-Sheet-December-2011.aspx)).

One of the primary applications for the finished device will be the rapid screening of traumatic brain injury patients before using more expensive and busy CT and MRI imaging techniques. In cases where CT and MRI imaging facilities aren't available, such as battlefields or on the scene of accidents, the team believes near-infrared imaging will help to determine the urgency of patient transport and treatment, as well as provide a means of monitoring known hematomas at the bedside or outpatient clinic.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation